Volume 6.05 | Feb 10

Pancreatic Cell News 6.05 February 10, 2015
Pancreatic Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  PACN on Twitter
A Common Genetic Variation of Melanoma Inhibitory Activity-2 Labels a Subtype of Pancreatic Adenocarcinoma with High Endoplasmic Reticulum Stress Levels
Scientists demonstrate that HNF1 homeobox A and melanoma inhibitory activity 2 (MIA2) are expressed in a subset of human pancreatic ductal adenocarcinoma (PDAC) tissues and that HNF1A induced MIA2 in vitro. They identified a common germline variant of MIA2 associated with a secretory defect of the MIA2 protein in PDAC cells. [Sci Rep] Full Article
Free Cell Stem Cell Poster: Directed Differentiation of ESCs/iPSCs
PUBLICATIONS (Ranked by impact factor of the journal)

Long-Term Pancreatic Beta Cell Exposure to High Levels of Glucose but Not Palmitate Induces DNA Methylation within the Insulin Gene Promoter and Represses Transcriptional Activity
Scientists investigated insulin promoter DNA methylation in an over-nutrition state. INS-1 cells were cultured under normal-culture-glucose or experimental-high-glucose conditions for 14 days, with or without 0.4 mmol/l palmitate. [PLoS One] Full Article

MicroRNA-185 Targets SOCS3 to Inhibit Beta-Cell Dysfunction in Diabetes
Researchers investigated the role of microRNA-185 (miR-185) in diabetes. Overexpression of miR-185 enhanced insulin secretion of pancreatic β-cells, promoted cell proliferation and protected cells from apoptosis. [PLoS One] Full Article

Persistent Infection of Human Pancreatic Cells with Coxsackievirus B4 Is Cured by Fluoxetine
Fluoxetine was reported to inhibit the replication of group B Coxsackievirus (CVB)1-3, which prompted the authors to study the in vitro antiviral activity of fluoxetine against CVB4 in models of acute infection. In addition they took advantage of a chronically CVB4-infected Panc-1 cell line to evaluate the antiviral effect of fluoxetine in a model of persistent CVB4 infection. [Antiviral Res] Abstract

Sesamin Suppresses STZ Induced INS-1 Cell Apoptosis through Inhibition of NF-κB Activation and Regulation of Bcl-2 Family Protein Expression
Researchers evaluated the effect of sesamin on streptozotocin (STZ) induced apoptosis in INS-1 cells and the possible mechanisms implicated. [Eur J Pharmacol] Abstract


LB-1 Exerts Antitumor Activity in Pancreatic Cancer by Inhibiting HIF-1α and Stat3 Signaling
Scientists explored how LB-1, a novel triptolide derivative, exerted its antitumor effect through blockade of hypoxia-inducible factor-1α (HIF-1α) and signal transducer and activator of transcription-3 (Stat3) signaling. They show that LB-1 was able to inhibit the proliferation and colony formation of Mia-PaCa2 and SW1990 cells. [J Cell Physiol] Abstract

mTOR Inhibition Induces EGFR Feedback Activation in Association with Its Resistance to Human Pancreatic Cancer
In vitro and in vivo experiments further indicated the combination of AZD8055 and erlotinib synergistically inhibited the mammalian target of rapamycin (mTOR) complex 1 (mTORC1)/C2 signaling pathway, epidermal growth factor receptor (EGFR)/AKT feedback activation, and cell growth, as well as suppressed the progression of pancreatic cancer in a xenograft model. [Int J Mol Sci] Abstract | Download Full Article

Evaluation of Ibuprofen Loaded Solid Lipid Nanoparticles and Its Combination Regimens for Pancreatic Cancer Chemoprevention
Scientists established the individual and combined chemopreventive potential of a widely used non-steroidal anti-inflammatory drug, ibuprofen, encapsulated in solid lipid nanoparticles for the chemoprevention of pancreatic cancer. [Int J Oncol] Abstract

BRD4 Promotes Pancreatic Ductal Adenocarcinoma Cell Proliferation and Enhances Gemcitabine Resistance
Researchers analyzed the effect of BRD4 on the cell progression and chemoresistance of pancreatic ductal adenocarcinoma (PDAC) and the novel mechanisms involved. They reveal that the expression of BRD4 was significantly upregulated in PDAC cell lines, compared to that in human pancreatic duct epithelial cells. [Oncol Rep] Abstract

Free Sample: TeSR™2 Defined, Feeder-Free and Xeno-Free Human ES and iPS Cell Medium
Cellular Stress Drives Pancreatic Plasticity
Recent research has reinvigorated enthusiasm for the harnessing of pancreatic plasticity for therapeutic application. The authors highlight key findings in this field and provide a perspective on possible exploitation of human pancreatic plasticity for therapeutic beta cell regeneration. [Sci Transl Med] Abstract

Visit our reviews page to see a complete list of reviews in the pancreatic cell research field.
Research Study at Banner MD Anderson Cancer Center Aims to Fight Pancreatic Cancer
A new clinical trial at Banner MD Anderson Cancer Center aims to test a new treatment to fight late-stage pancreatic cancer, one of the nation’s deadliest cancers. [Banner MD Anderson Cancer Center] Press Release

Celgene Announces Positive Recommendation by Scottish Medicines Consortium (SMC) for ABRAXANE® (Nab-Paclitaxel) in Combination with Gemcitabine for Patients with Metastatic Pancreatic Cancer
Celgene International Sàrl announced that ABRAXANE®, in combination with gemcitabine, has now received a positive recommendation for the treatment of metastatic pancreatic cancer by the SMC within the National Health Service Scotland. [Celgene International Sàrl] Press Release

From our sponsor: Pluripotent cell isolation for regenerative medicine. Request a free wallchart from Nature.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW EMBO | EMBL Symposium: Frontiers in Stem Cells & Cancer
March 29-31, 2015
Heidelberg, Germany

Visit our events page to see a complete list of events in the pancreatic cell community.
NEW Director – Vector Production (Sangamo BioSciences, Inc.)

NEW Senior Process Development Engineer (Sangamo BioSciences, Inc.)

NEW Professor – Type 1 Diabetes (Karolinska Institute)

Scientist – Pluripotent Stem Cell Biology Endoderm Lineages (STEMCELL Technologies Inc.)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Assistant/Associate Professor – Endocrinology, Diabetes and Metabolism Research (University of Pennsylvania)

Postdoctoral Position – Type 1 Diabetes Research (KU Leuven)

Research Laboratory Technician – Diabetes (University of Massachusetts)

PhD Scholarships – Diabetes (Danish Diabetes Academy)

Postdoctoral Fellow – Wnt Signaling in Development and Disease (Van Andel Research Institute)

Postdoctoral Research Fellow – Post-Transcriptional Gene Regulation Governing Cancer Cell Behavior (Fred Hutchinson Cancer Research Center)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Pancreatic Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Pancreatic Cell News: Archives | Events | Contact Us